Generex Biotechnology Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1983-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.generex.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
- Conditions
- Type 2 Diabetes MellitusType 1 Diabetes Mellitus
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2013-03-20
- Lead Sponsor
- Generex Biotechnology Corp.
- Registration Number
- NCT00948493
Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin
Phase 3
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Generex Oral-lyn™Drug: Regular human insulin
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Generex Biotechnology Corp.
- Target Recruit Count
- 500
- Registration Number
- NCT00668850
- Locations
- 🇺🇸
Coastal Biomedical Research Inc. at Santa Monica, 2001 Santa Monica Blvd Suite 390W, California, United States
🇺🇸The Center for Diabetes & Endocrine Care at Hollywood, 1150 N. 35th Ave Suite 590, Florida, United States
🇺🇸Physicians Research Group at Indianapolis, 7400 North Shadeland Ave, Indiana, United States
News
No news found